Multiple Myeloma – Epidemiology – Mature Markets
DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of multiple myeloma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world.
DRG Epidemiology's multiple myeloma forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with multiple myeloma per year?
- Of all people diagnosed with multiple myeloma, how many in each country across the developed world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of multiple myeloma over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following multiple myeloma patient populations:
- Diagnosed incident cases.
- Diagnosed incident cases by stage distribution.
- Diagnosed incident cases by symptomatic status.
- Diagnosed first-line drug-treatable population.
- First-line drug-treatable population by transplant eligibility status.
- First-line transplant-eligible drug-treatment subpopulation.
- First-line transplant-ineligible drug-treatment subpopulation.
- Second-line drug-treatable subpopulation.
- Diagnosed second-line drug-treatable population.
- Diagnosed MGUS incident cases.
- Total MGUS prevalent cases.
… and more (details available on request).
Note: Coverage may vary by country and region.
Table of contents
- Multiple Myeloma - Epidemiology - Mature Markets
- Introduction
- Overview
- Diagnosed Incidence of Multiple Myeloma per 100,000 Among People of All Ages in 2020 and 2040ttttttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Multiple Myeloma Over the Next 20 Yearsttttttttttttt
- Overview
- Epidemiology Data
- Methods
- Diagnosed Incident Cases of Multiple Myeloma
- ISS Stage Distribution
- Diagnosed Incident Cases of Multiple Myeloma by Symptoms
- Asymptomatic Cases by Risk Stratification
- Asymptomatic Multiple Myeloma Progression to Symptomatic Multiple Myeloma
- Diagnosed Prevalent Cases of Multiple Myeloma
- Diagnosed Incident Cases of MGUS
- MGUS Prevalent Cases
- MGUS Progression to Multiple Myeloma
- Drug-Treatable Population and Percentage Drug-Treated
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Multiple Myeloma
- Studies Excluded from the Analysis of Multiple Myeloma
- Risk/Protective Factors
- Risk/Protective Factors for Multiple Myeloma
- Bibliography
- Glossary
- Literature Review
- Introduction
Ullas Ulahannan, M.P.H., is an associate epidemiologist at Clarivate. Previously, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. He earned a B.S. in nursing from Rajiv Gandhi University and an M.P.H. from Manipal University.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.